Comparing Lodoco vs Mitigare
| Lodoco (colchicine) | Mitigare (colchicine) |
|
|---|
| Lodoco (colchicine) | Mitigare (colchicine) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiovascular Risk Reduction. Lodoco may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Gout - Acute, Gout - Prophylaxis. Mitigare may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Lodoco (colchicine) | More about Mitigare (colchicine) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Be the first to share your experience with this drug. |
Mitigare has an average rating of 5.0 out of 10 from a total of 4 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Lodoco side effects |
View all Mitigare side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
|
None |
|||||||||||||||||
| Generic Availability | |||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Lodoco prices |
View all Mitigare prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other colchicine brands include: Colcigel Gel, Colcrys, Gloperba, Mitigare | Other colchicine brands include: Colcigel Gel, Colcrys, Gloperba, Lodoco | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
1.5 hours |
1.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 309 drugs are known to interact with Lodoco:
|
A total of 309 drugs are known to interact with Mitigare:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
June 16, 2023 |
September 26, 2014 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Repatha
Repatha is used to lower high cholesterol alongside dietary changes and to reduce the risk of major ...
Wegovy
Wegovy (semaglutide) an FDA-approved weekly injection for weight loss and to reduce heart risks ...
Jardiance
Jardiance (empagliflozin) is used to treat type 2 diabetes, chronic kidney disease and reduce the ...
Xarelto
Xarelto (rivaroxaban) is a factor Xa inhibitor used to reduce the risk of blood clots and stroke in ...
Rybelsus
Rybelsus tablets are used to improve blood sugar control in adults with type 2 diabetes, and may ...
Trulicity
Trulicity is an injectable diabetes medicine that is used together with diet and exercise to ...
Brilinta
Brilinta (ticagrelor) is used to lower your risk of having a stroke or serious heart problems after ...
Victoza
Victoza helps control blood sugar levels and reduce the risk of serious heart problems in people ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.